Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP946340.RAAWXfDlg_zsgcwQSwyLK5f97n_dR3Hn3HnvNLk30FIjU130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946340.RAAWXfDlg_zsgcwQSwyLK5f97n_dR3Hn3HnvNLk30FIjU130_provenance.
• NP279114.RABKV8wIBp76EaEQd88D2CuZ6_OLb9hsbsnrOZNehi2Ns130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279114.RABKV8wIBp76EaEQd88D2CuZ6_OLb9hsbsnrOZNehi2Ns130_provenance.
• NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.
• NP1085333.RAD9zQCbo805ktmktc9EmACWIlA0QBPkLcx4CPZbtGPKo130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1085333.RAD9zQCbo805ktmktc9EmACWIlA0QBPkLcx4CPZbtGPKo130_provenance.
• NP1085334.RADkZWVVnTcf--W5Oq9XKJMy55Ox1mQy4wHyBEzYndfn4130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1085334.RADkZWVVnTcf--W5Oq9XKJMy55Ox1mQy4wHyBEzYndfn4130_provenance.
• assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP287458.RAGX1rigUvH05VII0wSNj5hLej6wtzvJ0jB0uAtql1FNk130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP287458.RAGX1rigUvH05VII0wSNj5hLej6wtzvJ0jB0uAtql1FNk130_provenance.
• NP1085337.RAR47AGT9WVPN4Xc9IREiAIxV9SB2fPWeY09Q_4dufm5s130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1085337.RAR47AGT9WVPN4Xc9IREiAIxV9SB2fPWeY09Q_4dufm5s130_provenance.
• assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1085338.RANg36iT6OqmVht0scgYu3wPE3b0efW8VZ_4C158R_pVc130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1085338.RANg36iT6OqmVht0scgYu3wPE3b0efW8VZ_4C158R_pVc130_provenance.
• NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.
• NP1085335.RAlmHL9rgUhHncqHPL_Rm-M2oLZxNgJ9dahcBkEFBP_JE130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1085335.RAlmHL9rgUhHncqHPL_Rm-M2oLZxNgJ9dahcBkEFBP_JE130_provenance.